Cellular delivery of relaxin-2 mRNA as a potential treatment for kidney fibrosis
Source abstract
Abstract
Renal fibrosis is a pathological feature of chronic kidney disease and its progression correlates with kidney function impairment. Since there are currently no specific therapies for renal fibrosis, we explored whether inducing local production of the anti-fibrotic molecule relaxin-2 in kidney cells has potential as a strategy for suppressing the development of renal fibrosis. Our study examined whether delivery of relaxin-2 mRNA to kidney cells in vitro and in vivo could inhibit mechanisms leading to renal fibrosis. Transfecting relaxin-2 mRNA into cultured kidney cells inhibited fibrotic responses to TGF-β1 in an autocrine or paracrine manner by reducing fibrotic gene expression in kidney tubules, and reducing proliferation in kidney fibroblasts and mesangial cells. Similarly, cubosomes assisted delivery of relaxin-2 mRNA to mouse kidneys alleviated the fibrosis and inflammation associated with renal injury following unilateral ureter obstruction (UUO). Therefore, relaxin-2 mRNA exhibits potential as a novel therapy for inhibiting fibrosis and inflammation in chronic kidney disease.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pregnancy-related medical research · Childhood Cancer Survivors' Quality of Life
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Chronic inflammation in end-stage renal disease and dialysis10.1093/ndt/gfy175 ↗
2. Relaxin family peptides and their receptors10.1152/physrev.00001.2012 ↗
3. Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist10.1096/fj.03-1120fje ↗
4. The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease10.1152/ajpregu.00528.2012 ↗
5. Serelaxin in acute heart failure: most recent update on clinical and preclinical evidence10.1111/1755-5922.12231 ↗
6. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)10.1186/s13063-020-4203-9 ↗
7. mRNA-based therapeutics: powerful and versatile tools to combat diseases10.1038/s41392-022-01007-w ↗
8. mRNA-based therapeutics--developing a new class of drugs10.1038/nrd4278 ↗
9. mRNA: a novel avenue to antibody therapy?10.1016/j.ymthe.2019.03.002 ↗
10. Lipid nanoparticles for mRNA delivery
11. Cubosomes: the next generation of smart lipid nanoparticles?10.1002/anie.201804067 ↗
12. Annexin V-containing cubosomes for targeted early detection of apoptosis in degenerative retinal tissue10.1039/C8TB02465K ↗
13. A polytherapy based approach to combat antimicrobial resistance using cubosomes10.1038/s41467-022-28012-5 ↗
14. Targeted detection of phosphatidylserine in biomimetic membranes and in vitro cell systems using annexin V-containing cubosomes10.1016/j.biomaterials.2013.07.042 ↗
15. Mesenchymal stem cells deliver exogenous MicroRNA-let7c via exosomes to attenuate renal fibrosis10.1038/mt.2016.90 ↗
16. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis10.1093/ndt/gfh441 ↗
17. Deletion of nicotinamide nucleotide transhydrogenase: a new quantitive trait locus accounting for glucose intolerance in C57BL/6J mice10.2337/db06-0358 ↗
18. A primary culture of mouse proximal tubular cells, established on collagen-coated membranes10.1152/ajprenal.00363.2006 ↗
19. Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy10.1096/fj.14-254789 ↗
20. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo10.1210/en.2004-0209 ↗
21. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis10.1210/en.2010-0286 ↗
22. Relaxin inhibits early steps in vascular inflammation10.1016/j.regpep.2010.09.001 ↗
23. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial10.1016/S0140-6736(12)61855-8 ↗
24. Effects of serelaxin in patients with acute heart failure10.1056/NEJMoa1801291 ↗
25. The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration10.1023/A:1018901009062 ↗
26. Structural characterization by mass spectrometry of native and recombinant human relaxin10.1002/bms.1200191105 ↗
27. Production of human pro-relaxin H2 in the yeast Pichia pastoris10.1186/s12896-016-0319-0 ↗
28. Synthetic relaxins10.1016/j.cbpa.2014.09.014 ↗
29. Overcoming endocytosis deficiency by cubosome nanocarriers10.1021/acsabm.9b00187 ↗
30. Treatment of ischemic neuronal death by introducing brain-derived neurotrophic factor mRNA using polyplex nanomicelle10.1016/j.biomaterials.2021.120681 ↗
31. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis10.1073/pnas.2116271119 ↗
32. WNT1-inducible signaling pathway protein 1 regulates kidney inflammation through the NF-kappaB pathway10.1042/CS20210663 ↗
33. WNT1-inducible-signaling pathway protein 1 regulates the development of kidney fibrosis through the TGF-beta1 pathway10.1096/fj.202000953R ↗
34. Unilateral ureteral obstruction as a model to investigate fibrosis-attenuating treatments10.3390/biom9040141 ↗
35. Refining the unilateral ureteral obstruction mouse model: No sham, no shame10.1177/0023677220909401 ↗